Multidisciplinary Session
MS 1 - Venous thromboembolic disease
Lectures
MS 1 - Haematology management in VTE: which patients for intervention, which patients for conservative? My clinical perspective
09:53R. Gilmore, Galway / IE
Learning Objectives
1. To describe why some patients are more suitable for intervention and others less so.
2. To discuss the anticoagulation management around catheter directed thrombolysis and why fibrinogen even matters.
3. To discuss anticoagulation regimes post op and when to choose low molecular weight heparin vs warfarain vs NOAC.
MS 1 - Patient selection and interventional options in deep vein thrombosis
09:35D. Mulholland, London / UK
Learning Objectives
1. To understand which patients I am keen to treat and why.
2. To show which treatment options I favour.
3. To share my worst disaster in DVT intervention and how we managed it.
MS 1 - Patient selection and interventional options in pulmonary embolus?
09:52S. Kee, Dublin / IE
Learning Objectives
1. To understand which patients I am keen to treat and why.
2. To show which treatment options I favour.
3. To share my worst disaster in PE intervention and how we managed it.
MS 1 - Precise, patient-directed imaging in DVT and PE
09:23C. Arnoldussen, Maastricht / NL
Learning Objectives
1. To describe the various imaging modalities for DVT and PE.
2. To describe my preferred modalities for DVT and PE.
3. To discuss future directions, particularly with respect to MRV and thrombus aging.
MS 1 - Multidisciplinary case presentation
06:55G. O'Sullivan, Galway / IE
2. To discuss the anticoagulation management around catheter directed thrombolysis and why fibrinogen even matters.
3. To discuss anticoagulation regimes post op and when to choose low molecular weight heparin vs warfarain vs NOAC.
2. To show which treatment options I favour.
3. To share my worst disaster in DVT intervention and how we managed it.
2. To show which treatment options I favour.
3. To share my worst disaster in PE intervention and how we managed it.
2. To describe my preferred modalities for DVT and PE.
3. To discuss future directions, particularly with respect to MRV and thrombus aging.